These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 14534734)

  • 1. Tumour MHC class I downregulation and immunotherapy (Review).
    Bubeník J
    Oncol Rep; 2003; 10(6):2005-8. PubMed ID: 14534734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MHC class I down-regulation: tumour escape from immune surveillance? (review).
    Bubeník J
    Int J Oncol; 2004 Aug; 25(2):487-91. PubMed ID: 15254748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.
    Mikysková R; Bubeník J; Vonka V; Smahel M; Indrova M; Bieblová J; Símová J; Jandlová T
    Int J Oncol; 2005 Feb; 26(2):521-7. PubMed ID: 15645139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of surface HLA-A,B,C molecules in tumour immunity.
    Möller P; Hämmerling GJ
    Cancer Surv; 1992; 13():101-27. PubMed ID: 1423320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with MHC class I-negative but not -positive HPV16-associated tumour cells inhibits growth of MHC class I-negative tumours.
    Reinis M; Símová J; Indrová M; Bieblová J; Pribylová H; Moravcová S; Jandlová T; Bubeník J
    Int J Oncol; 2007 Apr; 30(4):1011-7. PubMed ID: 17332942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of MHC class I-deficient tumors.
    Reiniš M
    Future Oncol; 2010 Oct; 6(10):1577-89. PubMed ID: 21062157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours.
    Indrová M; Símová J; Bieblová J; Bubeník J; Reinis M
    Oncol Rep; 2011 Jan; 25(1):281-8. PubMed ID: 21109988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural killer cells infiltrating colorectal cancer and MHC class I expression.
    Sandel MH; Speetjens FM; Menon AG; Albertsson PA; Basse PH; Hokland M; Nagelkerke JF; Tollenaar RA; van de Velde CJ; Kuppen PJ
    Mol Immunol; 2005 Feb; 42(4):541-6. PubMed ID: 15607811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The biological consequences of altered MHC class I expression in tumours.
    Algarra I; Gaforio JJ; Cabrera T; Collado A; Garrido F
    J Biol Regul Homeost Agents; 1999; 13(2):90-6. PubMed ID: 10503731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours.
    Indrová M; Bieblová J; Jandlová T; Vonka V; Pajtasz-Piasecka E; Reinis M
    Int J Oncol; 2006 Jan; 28(1):253-9. PubMed ID: 16328003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways.
    Cheng WF; Hung CF; Lee CN; Su YN; Chang MC; He L; Wu TC; Chen CA; Hsieh CY
    Eur J Immunol; 2004 Jul; 34(7):1892-900. PubMed ID: 15214037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [MHC tetramers: tracking specific immunity].
    Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
    Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Porcine T lymphocytes and NK cells--an update.
    Gerner W; Käser T; Saalmüller A
    Dev Comp Immunol; 2009 Mar; 33(3):310-20. PubMed ID: 18601948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TCR-independent cytokine stimulation induces non-MHC-restricted T cell activity and is negatively regulated by HLA class I.
    von Geldern M; Simm B; Braun M; Weiss EH; Schendel DJ; Falk CS
    Eur J Immunol; 2006 Sep; 36(9):2347-58. PubMed ID: 16909431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation.
    Leffers N; Lambeck AJ; de Graeff P; Bijlsma AY; Daemen T; van der Zee AG; Nijman HW
    Gynecol Oncol; 2008 Sep; 110(3):365-73. PubMed ID: 18571704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure, expression and function of HLA-G in renal cell carcinoma.
    Seliger B; Schlaf G
    Semin Cancer Biol; 2007 Dec; 17(6):444-50. PubMed ID: 17707652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
    Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
    Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma.
    Wu JY; Ernstoff MS; Hill JM; Cole B; Meehan KR
    Cytotherapy; 2006; 8(2):141-8. PubMed ID: 16698687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective MHC expression in tumours modulates adaptive and innate antitumour responses.
    Rees RC; Mian S
    Cancer Immunol Immunother; 1999 Oct; 48(7):374-81. PubMed ID: 10501850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors.
    Raja Gabaglia C; Diaz de Durana Y; Graham FL; Gauldie J; Sercarz EE; Braciak TA
    Cancer Res; 2007 Mar; 67(5):2290-7. PubMed ID: 17332360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.